SuperworthBolt Biotherapeutics EPS BOLT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$16.44
- Latest quarter, Q2 FY26
- −$4.57
- Fiscal year 2025
- −$17.78
Bolt Biotherapeutics' earnings per share was −$16.44 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$4.57.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$17.78 | n/a |
| FY2024 | −$32.97 | n/a |
| FY2023 | −$36.60 | n/a |
| FY2022 | −$47.20 | n/a |
| FY2021 | −$62.80 | n/a |
| FY2020 | −$575.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$4.57 | n/a | −$16.44 | |
| Q1 FY26 | −$4.31 | n/a | −$16.33 | |
| Q4 FY25 | −$3.84 | n/a | −$17.78 | |
| Q3 FY25 | −$3.72 | n/a | −$22.26 | |
| Q2 FY25 | −$4.46 | n/a | −$26.47 | |
| Q1 FY25 | −$5.76 | n/a | −$33.13 | |
| Q4 FY24 | −$8.32 | n/a | −$32.97 | |
| Q3 FY24 | −$7.93 | n/a | −$34.05 | |
| Q2 FY24 | −$11.12 | n/a | −$34.72 | |
| Q1 FY24 | −$5.60 | n/a | −$33.20 | |
| Q4 FY23 | −$9.40 | n/a | −$36.60 | |
| Q3 FY23 | −$8.60 | n/a | −$37.80 |
Against its peers
Companies in Drug Manufacturers - General nearest Bolt Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| BOLTBolt Biotherapeutics | −$16.44 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Bolt Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.